Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics

Journal of Biological Chemistry

Volumn 290, Issue 50, 2015, Pages 29732-29741

  Yadav, Daniela Bumbaca ^a   Sharma, Vikas K ^a   Boswell, Charles Andrew ^a   Hotzel, Isidro ^a   Tesar, Devin ^a   Shang, Yonglei ^a   Ying, Yong ^a   Fischer, Saloumeh K ^a   Grogan, Jane L ^a   Chiang, Eugene Y ^a   Urban, Konnie ^a   Ulufatu, Sheila ^a   Khawli, Leslie A ^a   Prabhu, Saileta ^a   Joseph, Sean ^a   Kelley, Robert F ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; MAMMALS; MONOCLONAL ANTIBODIES; PHARMACOKINETICS;

CYNOMOLGUS MONKEYS; EMPIRICAL MODEL; POSITIVELY CHARGED; RISK ASSESSMENT TOOL; VARIABLE REGIONS;

RISK ASSESSMENT;

AMINO ACID; ANTIBODY; HUMAB4D5 8 ANTIBODY; LYMPHOTOXIN ALPHA ANTIBODY; TOXIN ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN VARIABLE REGION;

ANIMAL EXPERIMENT; ANTIBODY VARIABLE REGION CHARGE; AREA UNDER THE CURVE; ARTICLE; BIOENGINEERING; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; MACACA FASCICULARIS; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; PROTEIN MODIFICATION; RAT; RISK ASSESSMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ANIMAL; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN VARIABLE REGION; MACACA FASCICULARIS; PHARMACOKINETICS; RISK ASSESSMENT;

EID: 84949637685     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.692434     Document Type: Article

References (46)

1. Reichert, J. M. (2012) Marketed therapeutic antibodies compendium. mAbs 4, 413-415
2. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., and Rosenthal, J. (2014) Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40-51
3. Bumbaca, D., Boswell, C. A., Fielder, P. J., and Khawli, L. A. (2012) Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J. 14, 554-558
4. Cao, Y., and Jusko, W. J. (2014) Incorporating target-mediated drug disposition in a minimal physiologically based pharmacokinetic model for monoclonal antibodies. J. Pharmacokinet. Pharmacodyn. 41, 375-387
5. Davda, J. P., and Hansen, R. J. (2010) Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. mAbs 2, 576-588
6. Wang, W., Wang, E. Q., and Balthasar, J. P. (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84, 548-558
7. Chirmule, N., Jawa, V., and Meibohm, B. (2012) Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 14, 296-302
8. Everds, N., Li, N., Bailey, K., Fort, M., Stevenson, R., Jawando, R., Salyers, K., Jawa, V., Narayanan, P., Stevens, E., He, C., Nguyen, M. P., Tran, S., Doyle, N., Poitout-Belissent, F., et al. (2013) Unexpected thrombocytopenia and anemia in cynomolgus monkeys induced by a therapeutic human monoclonal antibody. Toxicol. Pathol. 41, 951-969
9. Santostefano, M. J., Kirchner, J., Vissinga, C., Fort, M., Lear, S., Pan, W. J., Prince, P. J., Hensley, K. M., Tran, D., Rock, D., Vargas, H. M., Narayanan, P., Jawando, R., Rees, W., Reindel, J. F., et al. (2012) Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody. Toxicol. Pathol. 40, 899-917
10. Bumbaca, D., Wong, A., Drake, E., Reyes, A. E., 2nd., Lin, B. C., Stephan, J.-P., Desnoyers, L., Shen, B.-Q., and Dennis, M. S. (2011) Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. mAbs 3, 376-386
11. Xin, Y., Li, J., Wu, J., Kinard, R., Weekes, C. D., Patnaik, A., Lorusso, P., Brachmann, R., Tong, R. K., Yan, Y., Watts, R., Bai, S., and Hegde, P. S. (2012) Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors. Clin. Cancer Res. 18, 6040-6048
12. Vugmeyster, Y., Szklut, P., Wensel, D., Ross, J., Xu, X., Awwad, M., Gill, D., Tchistiakov, L., and Warner, G. (2011) Complex pharmacokinetics of a humanized antibody against human amyloid β peptide, anti-Aβ Ab2, in nonclinical species. Pharm. Res. 28, 1696-1706
13. Pippig, S. D., Brockmeyer, C., and Zoubek, R. E. (2014) in Biosimilar Monoclonal Antibodies (Dubel, S., and Reichert, J. M., eds) Wiley-Blackwell, Hoboken, NJ
14. Deng, R., Iyer, S., Theil, F. P., Mortensen, D. L., Fielder, P. J., and Prabhu, S. (2011) Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? mAbs 3, 61-66
15. Dong, J. Q., Salinger, D. H., Endres, C. J., Gibbs, J. P., Hsu, C. P., Stouch, B. J., Hurh, E., and Gibbs, M. A. (2011) Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin. Pharmacokinet. 50, 131-142
16. Hotzel, I., Theil, F. P., Bernstein, L. J., Prabhu, S., Deng, R., Quintana, L., Lutman, J., Sibia, R., Chan, P., Bumbaca, D., Fielder, P., Carter, P. J., and Kelley, R. F. (2012) A strategy for risk mitigation of antibodies with fast clearance. mAbs 4, 753-760
17. Sharma, V. K., Patapoff, T. W., Kabakoff, B., Pai, S., Hilario, E., Zhang, B., Li, C., Borisov, O., Kelley, R. F., Chorny, I., Zhou, J. Z., Dill, K. A., and Swartz, T. E. (2014) In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc. Natl. Acad. Sci. U.S.A. 111, 18601-18606
18. Lee, H. J., and Pardridge, W. M. (2003) Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging. Bioconjug. Chem. 14, 546-553
19. Pardridge, W. M., Kang, Y. S., Yang, J., and Buciak, J. L. (1995) Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization. J. Pharm. Sci. 84, 943-948
20. Herve, F., Ghinea, N., and Scherrmann, J. M. (2008) CNS delivery via adsorptive transcytosis. AAPS J. 10, 455-472
21. Khawli, L. A., Glasky, M. S., Alauddin, M. M., and Epstein, A. L. (1996) Improved tumor localization and radioimaging with chemically modified monoclonal antibodies. Cancer Biother. Radiopharm. 11, 203-215
22. Kobayashi, H., Le, N., Kim, I. S., Kim, M. K., Pie, J. E., Drumm, D., Paik, D. S., Waldmann, T. A., Paik, C. H., and Carrasquillo, J. A. (1999) The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res. 59, 422-430
23. Igawa, T., Tsunoda, H., Tachibana, T., Maeda, A., Mimoto, F., Moriyama, C., Nanami, M., Sekimori, Y., Nabuchi, Y., Aso, Y., and Hattori, K. (2010) Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng. Des. Sel. 23, 385-392
24. Sampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., Yoshihashi, K., Harada, A., Funaki, M., Haraya, K., Tachibana, T., et al. (2013) Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 8, e57479
25. Chiang, E. Y., Kolumam, G., McCutcheon, K. M., Young, J., Lin, Z., Balazs, M., and Grogan, J. L. (2012) In vivo depletion of lymphotoxin-α expressing lymphocytes inhibits xenogeneic graft-versus-host-disease. PLoS One 7, e33106
26. Shalaby, M. R., Shepard, H. M., Presta, L., Rodrigues, M. L., Beverley, P. C., Feldmann, M., and Carter, P. (1992) Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. 175, 217-225
27. Tabrizi, M., Bornstein, G. G., and Suria, H. (2010) Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 12, 33-43
28. Davies Cde, L., Berk, D. A., Pluen, A., and Jain, R. K. (2002) Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br. J. Cancer 86, 1639-1644
29. Sudhamsu, J., Yin, J., Chiang, E. Y., Starovasnik, M. A., Grogan, J. L., and Hymowitz, S. G. (2013) Dimerization of LTβR by LTα1β2 is necessary and sufficient for signal transduction. Proc. Natl. Acad. Sci. U.S.A. 110, 19896-19901
30. Cho, H. S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., Jr., and Leahy, D. J. (2003) Structure of the extracellular region of HER2 alone and in complex with the herceptin Fab. Nature 421, 756-760
31. Kabat, E. A., Wu, T. T., Perry, H., Gottesman, K., and Foeller, C. (1991) Sequences of Proteins of Immunological Interest, 5th Ed., NIH Publication, Bethesda
32. Kelley, R. F., and Meng, Y. G. (2012) Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function. Methods Mol. Biol. 901, 277-293
33. Pantua, H., Diao, J., Ultsch, M., Hazen, M., Mathieu, M., McCutcheon, K., Takeda, K., Date, S., Cheung, T. K., Phung, Q., Hass, P., Arnott, D., Hongo, J. A., Matthews, D. J., Brown, A., et al. (2013) Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J. Mol. Biol. 425, 1899-1914
34. Li, B., Tesar, D., Boswell, C. A., Cahaya, H. S., Wong, A., Zhang, J., Meng, Y. G., Eigenbrot, C., Pantua, H., Diao, J., Kapadia, S. B., Deng, R., and Kelley, R. F. (2014) Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. mAbs 6, 1255-1264
35. Boswell, C. A., Tesar, D. B., Mukhyala, K., Theil, F. P., Fielder, P. J., and Khawli, L. A. (2010) Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug. Chem. 21, 2153-2163
36. Schoch, A., Kettenberger, H., Mundigl, O., Winter, G., Engert, J., Heinrich, J., and Emrich, T. (2015) Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc. Natl. Acad. Sci. U.S.A. 112, 5997-6002
37. Mach, H., Gregory, S. M., Mackiewicz, A., Mittal, S., Lalloo, A., Kirchmeier, M., and Shameem, M. (2011) Electrostatic interactions of monoclonal antibodies with subcutaneous tissue. Ther. Deliv. 2, 727-736
38. Ober, R. J., Radu, C. G., Ghetie, V., and Ward, E. S. (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 13, 1551-1559
39. Boxenbaum, H. (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. 10, 201-227
40. Lin, J. H. (1995) Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 23, 1008-1021
41. Richter, W. F., Bhansali, S. G., and Morris, M. E. (2012) Mechanistic determinants of biotherapeutics absorption following s.c. administration. AAPS J. 14, 559-570
42. Bass, R. B., Miller, A. S., Gloor, S. L., and Falke, J. J. (2007) The PICM chemical scanning method for identifying domain-domain and proteinprotein interfaces: applications to the core signaling complex of E. coli chemotaxis. Methods Enzymol. 423, 3-24
43. Cunningham, B. C., and Wells, J. A. (1989) High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244, 1081-1085
44. Mehan, R. S., White, N. C., and Falke, J. J. (2003) Mapping out regions on the surface of the aspartate receptor that are essential for kinase activation. Biochemistry 42, 2952-2959
45. Miller, A. S., Kohout, S. C., Gilman, K. A., and Falke, J. J. (2006) CheA kinase of bacterial chemotaxis: chemical mapping of four essential docking sites. Biochemistry 45, 8699-8711
46. Sharp, L. L., Zhou, J., and Blair, D. F. (1995) Features of MotA proton channel structure revealed by tryptophan-scanning mutagenesis. Proc. Natl. Acad. Sci. U.S.A. 92, 7946-7950